Andarine

Описание

Andarine, also known as S4 or S-4, is a selective androgen receptor modulator that was developed to treat muscle wasting diseases, and cancer patients who were wasting away. S-4 is an anabolic agonist that is effective and does not have the same side effects as anabolic-androgenic steroids. Its effectiveness is primarily due to its substrate affinity for 5α-reductase, which produces DHT in the prostate. Unfortunately the benefits that SARMs such as andarine (S-4) may provide to clinical medicine have the potential for misuse in sports where athletes and/or their handlers may seek to gain unfair advantage with the assumption that these compounds are undetectable by anti-doping laboratories. SARMs are therefore prohibited for use by the International Federation of Horseracing Authorities and the World Anti-Doping Agency (WADA).

Химические свойства

Pale Yellow Solid

Использование

Andarine is a potent and tissue-selective androgen receptor modulator (SARM) that is commonly used for lean gains, muscle hardening, and fat loss. Unlike other normies, it delivers impressive results without posing any serious risks to health.

Определение

ChEBI: Andarine is an anilide and a member of acetamides. It is a non-steroidal selective androgen receptor modulator.

преимущество

Andarine (S4) has a lot of great benefits and this is probably what you are most interested in.
The Andarine benefits are:
Increased muscle mass
Fat loss
Faster recovery
Body recomposition
Increased strength

Побочные эффекты

Andarine has gone through quite a bit of research but not as much as other SARMs such as LGD 4033 or Ostarine. From the studies so far and from the anecdotal evidence from people that use it we can tell that there are two side effects.
S4 side effects:
Suppression
Impaired vision

Синтез

Andarine was prepared from N-[4-Nitro-3-(trifluoromethyl)phenyl]-(2R)-3-bromo-2-hydroxy-2-methylpropanamide  (0.37 g, 1.0 mmol), 4-acetamidophenol (0.23 g, 1.5 mmol) K2CO3 (0.28 g, 2.0 mmol), and 10% of benzyltributylammonium chloride as a phase transfer catalyst in 20 mL of methyl ethyl ketone was heated at reflux overnight under argon. The reaction was followed by TLC, the resulting mixture was filtered through Celite, and concentrated in vacuo to dryness. Purification by flash column chromatography on silica gel (hexanes-ethyl acetate, 3:1) yielded 0.38 g (86%) (Rf=0.18 hexanes-ethyl acetate, 3:1) of the desired compound as a light yellow powder: mp 70-74° C.

Клиническое исследование

The pharmacological activity of andarine suggest the great potential of andarine in the development of the clinically available SARMs, which offers unique therapeutic advantages over their steroidal counterparts and an exciting opportunity to differentially regulate the androgen effects in various target tissues, thus minimizing the interference to normal. Thus, andarine has promising in advanced clinical trials that aim to treat age-related maladies and to counteract symptoms of severe diseases such as sarcopenia and cancer cachexia.
However, andarine may be misused in sports where athletes and/or their handlers may seek to gain unfair advantage. Therefore, andarine as agonist is prohibited for use by the International Federation of Horseracing Authorities and the World Anti-Doping Agency.

Регуляторный статус

Andarine also named SARM S-4, classified in the S1 class of the WADA prohibited list.
US: Andarine is not listed specifically in the Schedules to the US Controlled Substances Act and is not mentioned anywhere on the DEA website.
United Nations: The substance is not listed specifically on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.
Canadian Status: Andarine is not currently listed in the CDSA. The substance has been reported to be used for the treatment of muscle wasting, osteoporosis and begning prostatic hyperplaysia and displays androgenic and anabolic activity1-3 . 2 3However, since andarine is not a steroid, it cannot be included uner item 23 of Schedule IV to the CDSA.